Omeprazole sulfone (BioDeep_00000486362)
代谢物信息卡片
Omeprazole sulfone
化学式: C17H19N3O4S (361.10962140000004)
中文名称: 奥美拉唑砜
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CN=C(C(=C1OC)C)CS(=O)(=O)C2=NC3=C(N2)C=C(C=C3)OC
InChI: InChI=1S/C17H19N3O4S/c1-10-8-18-15(11(2)16(10)24-4)9-25(21,22)17-19-13-6-5-12(23-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:166518
- PubChem: 145900
- Metlin: METLIN1634
- ChEMBL: CHEMBL1344
- CAS: 88546-55-8
- RefMet: Omeprazole sulfone
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sebastian Trousil, Patrizia Lee, Robert J Edwards, Lynn Maslen, Jingky P Lozan-Kuehne, Ramya Ramaswami, Eric O Aboagye, Stephen Clarke, Christopher Liddle, Rohini Sharma. Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.
British journal of pharmacology.
2019 09; 176(18):3712-3722. doi:
10.1111/bph.14776. [PMID: 31236938] - Lateef Ahmad, Zafar Iqbal, Yasar Shah, Shabnam Nazir, Abad Khan, Muhammad Imran Khan, Abbas Khan, Fazli Khuda, Ismail Khan. Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.
Pakistan journal of pharmaceutical sciences.
2018 Jul; 31(4):1363-1374. doi:
. [PMID: 30033421] - Alessandra Rossi, Luca Castrati, Paolo Colombo, Lisa Flammini, Elisabetta Barocelli, Ruggero Bettini, Lisa Elviri. Development and validation of a DESI-HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study.
Drug testing and analysis.
2016 Feb; 8(2):208-13. doi:
10.1002/dta.1805. [PMID: 25922056] - Juan José Berzas Nevado, Gregorio Castañeda Peñalvo, Rosa María Rodríguez Dorado, Virginia Rodríguez Robledo. Simultaneous determination of omeprazole and their main metabolites in human urine samples by capillary electrophoresis using electrospray ionization-mass spectrometry detection.
Journal of pharmaceutical and biomedical analysis.
2014 Apr; 92(?):211-9. doi:
10.1016/j.jpba.2013.12.020. [PMID: 24530982] - Satoshi Yamada, Hideo Shiohira, Norio Yasui-Furukori, Tomonori Tateishi, Yumiko Akamine, Tsukasa Uno. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
European journal of clinical pharmacology.
2013 Jul; 69(7):1423-8. doi:
10.1007/s00228-013-1480-1. [PMID: 23435615] - Yoshiyuki Shirasaka, Jennifer E Sager, Justin D Lutz, Connie Davis, Nina Isoherranen. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.
Drug metabolism and disposition: the biological fate of chemicals.
2013 Jul; 41(7):1414-24. doi:
10.1124/dmd.113.051722. [PMID: 23620487] - Eileen B Lawson, Jerry C Wu, R Michael Baldwin, Magnus Ingelman-Sundberg, Staffan Rosenborg, Dong-Seok Yim, Ophelia Q P Yin, Edmund V Capparelli, Joseph D Ma. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
European journal of clinical pharmacology.
2012 Apr; 68(4):407-13. doi:
10.1007/s00228-011-1136-y. [PMID: 22009190] - V Michaud, E Ogburn, N Thong, A O Aregbe, T C Quigg, D A Flockhart, Z Desta. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.
Clinical pharmacology and therapeutics.
2012 Mar; 91(3):475-82. doi:
10.1038/clpt.2011.249. [PMID: 22318618] - Justin D Lutz, Nina Isoherranen. Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Jan; 40(1):159-68. doi:
10.1124/dmd.111.042200. [PMID: 22010218] - E Gebeyehu, E Engidawork, A Bijnsdorp, A Aminy, U Diczfalusy, E Aklillu. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
The pharmacogenomics journal.
2011 Apr; 11(2):130-7. doi:
10.1038/tpj.2010.16. [PMID: 20231858] - S K Jin, T S Kang, S O Eom, J-I Kim, H J Lee, J Roh. CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.
Journal of clinical pharmacy and therapeutics.
2009 Aug; 34(4):437-46. doi:
10.1111/j.1365-2710.2008.01012.x. [PMID: 19583677] - Katsuyoshi Sugimoto, Tsukasa Uno, Tomonori Tateishi. Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
European journal of clinical pharmacology.
2008 Jun; 64(6):583-7. doi:
10.1007/s00228-008-0461-2. [PMID: 18214455] - Lan Fan, Guo Wang, Lian-Sheng Wang, Yao Chen, Wei Zhang, Yuan-Fei Huang, Rui-Xue Huang, Dong-Li Hu, Dan Wang, Hong-Hao Zhou. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
Acta pharmacologica Sinica.
2007 Oct; 28(10):1685-92. doi:
10.1111/j.1745-7254.2007.00617.x. [PMID: 17883958] - Ia Hultman, Helene Stenhoff, Mathias Liljeblad. Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2007 Apr; 848(2):317-22. doi:
10.1016/j.jchromb.2006.10.074. [PMID: 17142113] - Naser L Rezk, Kevin C Brown, Angela D M Kashuba. A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2006 Dec; 844(2):314-21. doi:
10.1016/j.jchromb.2006.07.047. [PMID: 16920412] - Tomás Pérez-Ruiz, Carmen Martínez-Lozano, A Sanz, E Bravo, Raquel Galera. Determination of omeprazole, hydroxyomeprazole and omeprazole sulfone using automated solid phase extraction and micellar electrokinetic capillary chromatography.
Journal of pharmaceutical and biomedical analysis.
2006 Sep; 42(1):100-6. doi:
10.1016/j.jpba.2005.09.029. [PMID: 16280228] - Ylva Böttiger. Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4.
European journal of clinical pharmacology.
2006 Aug; 62(8):621-5. doi:
10.1007/s00228-006-0156-5. [PMID: 16791583] - Yanhua Zhang, Myong-Jin Kim, Joseph S Bertino, Anne N Nafziger, Edward M Sellers. Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults.
Journal of clinical pharmacology.
2006 Mar; 46(3):345-52. doi:
10.1177/0091270005284389. [PMID: 16490811] - Matthias Schwab, Ulrich Klotz, Ute Hofmann, Elke Schaeffeler, Andreas Leodolter, Peter Malfertheiner, Gerhard Treiber. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Clinical pharmacology and therapeutics.
2005 Dec; 78(6):627-34. doi:
10.1016/j.clpt.2005.08.017. [PMID: 16338278] - Yukio Ishizawa, Norio Yasui-Furukori, Takenori Takahata, Mutsuo Sasaki, Tomonori Tateishi. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Clinical pharmacokinetics.
2005; 44(11):1179-89. doi:
10.2165/00003088-200544110-00005. [PMID: 16231968] - Ophelia Q P Yin, Brian Tomlinson, Mary M Y Waye, Albert H L Chow, Moses S S Chow. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.
Pharmacogenetics.
2004 Dec; 14(12):841-50. doi:
10.1097/00008571-200412000-00007. [PMID: 15608563] - Hyung-Keun Roh, Pum-Soo Kim, Don-Haeng Lee, Gunnel Tybring, Mohamed Sagar, Chang-Shin Park, Rein Seensalu, Leif Bertilsson. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Basic & clinical pharmacology & toxicology.
2004 Sep; 95(3):112-9. doi:
10.1111/j.1742-7843.2004.950302.x. [PMID: 15447734] - Ophelia Q P Yin, Brian Tomlinson, Albert H L Chow, Mary M Y Waye, Moses S S Chow. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Journal of clinical pharmacology.
2004 Jun; 44(6):582-9. doi:
10.1177/0091270004265702. [PMID: 15145965] - D S Yim, J E Jeong, J Y Park. Assay of omeprazole and omeprazole sulfone by semi-microcolumn liquid chromatography with mixed-function precolumn.
Journal of chromatography. B, Biomedical sciences and applications.
2001 Apr; 754(2):487-93. doi:
10.1016/s0378-4347(01)00036-6. [PMID: 11339292] - W Tassaneeyakul, S Vannaprasaht, Y Yamazoe. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
British journal of clinical pharmacology.
2000 Feb; 49(2):139-44. doi:
10.1046/j.1365-2125.2000.00122.x. [PMID: 10671908] - G García-Encina, R Farrán, S Puig, L Martínez. Validation of an automated liquid chromatographic method for omeprazole in human plasma using on-line solid-phase extraction.
Journal of pharmaceutical and biomedical analysis.
1999 Nov; 21(2):371-82. doi:
10.1016/s0731-7085(99)00178-8. [PMID: 10703993] - U S Svensson, M Ashton, N H Trinh, L Bertilsson, X H Dinh, V H Nguyen, T N Nguyen, D S Nguyen, J Lykkesfeldt, D C Le. Artemisinin induces omeprazole metabolism in human beings.
Clinical pharmacology and therapeutics.
1998 Aug; 64(2):160-7. doi:
10.1016/s0009-9236(98)90149-7. [PMID: 9728896] - K L Rost, I Roots. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Hepatology (Baltimore, Md.).
1996 Jun; 23(6):1491-7. doi:
10.1002/hep.510230628. [PMID: 8675169] - K L Rost, J Brockmöller, F Esdorn, I Roots. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Journal of hepatology.
1995 Sep; 23(3):268-77. doi:
10.1016/s0168-8278(95)80005-0. [PMID: 8550990] - D R Sohn, K Kobayashi, K Chiba, K H Lee, S G Shin, T Ishizaki. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
The Journal of pharmacology and experimental therapeutics.
1992 Sep; 262(3):1195-202. doi:
NULL. [PMID: 1527724] - C G Regårdh, T Andersson, P O Lagerström, P Lundborg, I Skånberg. The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.
Therapeutic drug monitoring.
1990 Mar; 12(2):163-72. doi:
10.1097/00007691-199003000-00010. [PMID: 2315973] - J Naesdal, T Andersson, G Bodemar, R Larsson, C G Regårdh, I Skånberg, A Walan. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function.
Clinical pharmacology and therapeutics.
1986 Sep; 40(3):344-51. doi:
10.1038/clpt.1986.186. [PMID: 3742939] - G W Mihaly, P J Prichard, R A Smallwood, N D Yeomans, W J Louis. Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine.
Journal of chromatography.
1983 Dec; 278(2):311-9. doi:
10.1016/s0378-4347(00)84790-8. [PMID: 6668312]